Stay updated on APX005M + Pembrolizumab in Metastatic Melanoma Clinical Trial
Sign up to get notified when there's something new on the APX005M + Pembrolizumab in Metastatic Melanoma Clinical Trial page.

Latest updates to the APX005M + Pembrolizumab in Metastatic Melanoma Clinical Trial page
- ChecktodayNo Change Detected
- Check7 days agoNo Change Detected
- Check14 days agoChange DetectedAdded a new revision entry: Revision: v3.3.3 to the history. Removed HHS Vulnerability Disclosure and Revision: v3.3.2 from the history.SummaryDifference0.1%

- Check21 days agoNo Change Detected
- Check43 days agoChange DetectedThe history adds a Terminated status and indicates Results Posted with new Outcome Measures (Results). A new Revision: v3.3.2 entry dated 2025-11-21 is recorded.SummaryDifference0.6%

- Check50 days agoChange DetectedRemoved the government funding lapse notice that was previously displayed on the page. To avoid being alerted by small changes, set an alert condition by clicking below.SummaryDifference0.4%

- Check72 days agoChange DetectedA new history version (version 39) was added for NCT02706353 on 2025-10-08, indicating ongoing Quality Control Review and a results return date of 2025-10-23.SummaryDifference2%

- Check93 days agoChange Detected- Added a government-operating-status notice and a link to official sources, indicating the page may have dynamic status information. - Updated version from v3.1.0 to v3.2.0, signaling a new release.SummaryDifference9%

- Check100 days agoChange DetectedVersion update: from v3.0.2 to v3.1.0. This is a metadata revision with no substantive content changes.SummaryDifference0.2%

Stay in the know with updates to APX005M + Pembrolizumab in Metastatic Melanoma Clinical Trial
Enter your email address, and we'll notify you when there's something new on the APX005M + Pembrolizumab in Metastatic Melanoma Clinical Trial page.